Prescribing, Policies and Pathways
or
Medicine / Guideline | Indication | RAG rating | Document type | Place |
---|---|---|---|---|
2WW Non-Specific Symptoms pathway with CT Scans | n/a | Clinical pathways | South and West Hertfordshire | |
Abdomen and Pelvis CT to rule out Pancreatic Cancer | n/a | Decision document | South and West Hertfordshire | |
Anastrozole | Familial breast cancer | n/a | NICE technology appraisal | Hertfordshire and West Essex ICB |
Bladder-Renal Cancer | Suspected | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Brain and Central Nervous System Cancers | n/a | Clinical pathways | East and North Hertfordshire | |
Brain MRI for the exclusion of Brain and CNS Cancer | n/a | n/a | South and West Hertfordshire | |
Breast Cancer - Suspected (Adults >16 years) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Breast Screening Service | n/a | Patient information | Hertfordshire and West Essex ICB | |
Cannabidiol (Epidiyolex®) | Tertiary care indication (NHSE) Suitable for shared care between tertiary and secondary care providers. Adjunctive treatment with clobazam for treating seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS) | Red | Decision document | Hertfordshire and West Essex ICB |
Children's Cancer | n/a | Patient information | Hertfordshire and West Essex ICB | |
Chlorambucil | Cancer indications | Red | n/a | Hertfordshire and West Essex ICB |
Chlormethine gel | Mycosis fungoides-type cutaneous T-cell lymphoma (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Community Breast Pain | n/a | Clinical pathways | East and North Hertfordshire | |
CT Request and 2WW Non-Specific Symptoms Referral Pathway | n/a | Clinical pathways | South and West Hertfordshire | |
Dasatinib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD] spray (Sativex®) | Spasticity in multiple sclerosis (MS) | Red | Decision document | Hertfordshire and West Essex ICB |
Denosumab Xgeva® | Prevention of skeletal-related events (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Erlotinib | All indications (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
Etoposide | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Exemestane | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Faecal Immunochemical Test (FIT) process pathway for suspected Lower GI Cancer | n/a | Clinical pathways | Hertfordshire and West Essex ICB, South and West Hertfordshire | |
Fulvestrant | Locally advanced or metastatic breast cancer | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Goserelin | Prostate cancer - 2nd line | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Gynaecological Cancers - Suspected | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Haematological Cancer – Suspected | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Head and Neck Cancer - Suspected | n/a | Clinical pathways | East and North Hertfordshire | |
Ibandronic acid 50mg | Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Ibrutinib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Imatinib | All indications (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Lenalidomide | Multiple myeloma follicular lymphoma (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Letrozole | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Leuprorelin | Prostate cancer - 2nd line | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Lower GI/Colorectal Cancer Suspected | n/a | Clinical pathways | East and North Hertfordshire, South and West Hertfordshire | |
Lung Cancer - Suspected | n/a | Clinical pathways | East and North Hertfordshire, South and West Hertfordshire | |
Lymphoedema Services – Specialist treatment in the private sector | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Male LUTS | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Melphalan | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Mesna | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Methotrexate 10mg | Autoimmune disease | Double Red | n/a | Hertfordshire and West Essex ICB |
Methotrexate 2.5mg | Autoimmune disease | Amber protocol | Prescribing guideline | Hertfordshire and West Essex ICB |
Methoxsalen | Cancer, psoriasis | Red | n/a | Hertfordshire and West Essex ICB |
Mitomycin | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Mitotane | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Nabilone | Intractable chemotherapy induced nausea and vomiting | Red | Decision document | Hertfordshire and West Essex ICB |
Nintedanib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Palbociclib | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Peginterferon and ropeginterferon | Myeloproliferative neoplasms (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Pegvisomant | Acromegaly (NHSE tertiary centre only) | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Prostate Cancer - Suspected | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
PSA Pathway | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
Raloxifene | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Reducing medicines waste in care homes - Care home staff | Care homes | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
Relugolix (Orgovyx) | Hormone-sensitive prostate cancer | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Ruxolitinib | Myelofibrosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Sarcoma - Suspected Cancer | n/a | Clinical pathways | East and North Hertfordshire | |
Sativex® and other licensed cannabis -based medicinal products | Red | Decision document | Hertfordshire and West Essex ICB | |
Sirolimus oral | Transplant rejection (prescribe by brand) NHSE for existing patients | Amber protocol | n/a | Hertfordshire and West Essex ICB |
Skin Cancer Suspected - Pigmented Lesion/ Melanoma/ SCC/ BCC | n/a | Patient information | Hertfordshire and West Essex ICB | |
Sodium clodronate | Bone pain, hypercalcaemia of malignancy | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Tacrolimus oral | Transplant rejection (prescribe by brand) NHSE for existing patients | Amber protocol | n/a | Hertfordshire and West Essex ICB |
Tamoxifen | Familial breast cancer | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Thalidomide | Cancer (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Tioguanine | Leukaemia | Red | n/a | Hertfordshire and West Essex ICB |
Tretinoin | Cancer (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
Triptorelin as Decapeptyl SR®– Gonadorelin analogue of choice within licensed indications | Prostate cancer - 1st line | Green | n/a | Hertfordshire and West Essex ICB |
Urology Cancer - Suspected (excluding Prostate) | n/a | Clinical pathways | Hertfordshire and West Essex ICB |